The company will participate in a Fireside Chat on Monday, August 5th at 8am ET.
ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2024 on Monday, August 5, 2024 at 8:00 a.m. ET.
In addition to the fireside chats, management will be available to participate in virtual one-on-one meetings with eligible members of the investor community who have registered to attend the conference. If you are interested in scheduling a meeting with Outlook Therapeutics during the conference, please contact your BTIG representative.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and UK marketing authorization for the treatment of wet AMD. Outlook Therapeutics aims to commence the launch of LYTENAVA™ (bevacizumab gamma) in the EU and UK in the first quarter of 2025. In the United States, ONS-5010/LYTENAVA™ is investigational and is currently being evaluated in a non-inferiority trial for the treatment of wet AMD. If successful, this trial may provide sufficient data for Outlook to resubmit a BLA application to the US FDA. If approved in the United States, ONS-5010/LYTENAVA™ would be the first ophthalmic formulation approved for use in retinal indications, including wet AMD.
Investor Inquiries:
Genene Thomas
chief executive officer
JTC Team LLC
Phone: 833.475.8247
inquiry
